Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | multiple interactions | EXP | | 6480464 | [APC protein affects the susceptibility to 1, 2-Dimethylhydrazine] which results in decreased expression of ABI3BP mRNA | CTD | PMID:27840820 | 17beta-estradiol | decreases expression | ISO | RGD:1616439 | 6480464 | Estradiol results in decreased expression of ABI3BP mRNA | CTD | PMID:19484750 | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABI3BP mRNA | CTD | PMID:32741896 | 17beta-estradiol 3-benzoate | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABI3BP mRNA | CTD | PMID:32741896 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1616439 | 6480464 | Tetrachlorodibenzodioxin affects the expression of ABI3BP mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ABI3BP mRNA | CTD | PMID:34747641 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ABI3BP mRNA | CTD | PMID:32109520, PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1616439 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ABI3BP mRNA | CTD | PMID:26290441 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1349467 | 6480464 | Endosulfan inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ABI3BP mRNA] | CTD | PMID:26159488 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1349467 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ABI3BP mRNA | CTD | PMID:20106945, PMID:26159488 | 3,4-methylenedioxymethamphetamine | decreases expression | ISO | RGD:1616439 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in decreased expression of ABI3BP mRNA | CTD | PMID:26251327 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1349467 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ABI3BP mRNA | CTD | PMID:28628672 | 3-methylcholanthrene | decreases expression | ISO | RGD:1616439 | 6480464 | Methylcholanthrene results in decreased expression of ABI3BP mRNA | CTD | PMID:20713471 | 3-Nitrobenzanthrone | increases expression | ISO | RGD:1349467 | 6480464 | 3-nitrobenzanthrone results in increased expression of ABI3BP mRNA | CTD | PMID:34036453 | 4,4'-sulfonyldiphenol | increases expression | ISO | RGD:1616439 | 6480464 | bis(4-hydroxyphenyl)sulfone results in increased expression of ABI3BP mRNA | CTD | PMID:30951980 | 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:1616439 | 6480464 | Fenretinide results in decreased expression of ABI3BP mRNA | CTD | PMID:28973697 | aristolochic acid A | decreases expression | ISO | RGD:1349467 | 6480464 | aristolochic acid I results in decreased expression of ABI3BP mRNA | CTD | PMID:33212167 | arsane | multiple interactions | ISO | RGD:1349467 | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ABI3BP mRNA | CTD | PMID:32525701 | arsenic atom | multiple interactions | ISO | RGD:1349467 | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ABI3BP mRNA | CTD | PMID:32525701 | arsenite(3-) | multiple interactions | ISO | RGD:1349467 | 6480464 | arsenite inhibits the reaction [G3BP1 protein binds to ABI3BP mRNA] | CTD | PMID:32406909 | atrazine | affects methylation | EXP | | 6480464 | Atrazine affects the methylation of ABI3BP gene | CTD | PMID:28931070 | benzo[a]pyrene | decreases expression | ISO | RGD:1616439 | 6480464 | Benzo(a)pyrene results in decreased expression of ABI3BP mRNA | CTD | PMID:20713471, PMID:21569818 | benzo[a]pyrene | increases methylation | ISO | RGD:1616439 | 6480464 | Benzo(a)pyrene results in increased methylation of ABI3BP intron, Benzo(a)pyrene results in increased methylation of ABI3BP promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases methylation | ISO | RGD:1349467 | 6480464 | Benzo(a)pyrene results in decreased methylation of ABI3BP 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | multiple interactions | ISO | RGD:1616439 | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA | CTD | PMID:27858113 | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of ABI3BP mRNA | CTD | PMID:21839799 | benzo[a]pyrene | decreases expression | ISO | RGD:1349467 | 6480464 | Benzo(a)pyrene results in decreased expression of ABI3BP mRNA | CTD | PMID:20106945 | benzo[b]fluoranthene | multiple interactions | ISO | RGD:1616439 | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA | CTD | PMID:27858113 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of ABI3BP mRNA | CTD | PMID:25181051 | bisphenol A | multiple interactions | ISO | RGD:1349467 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of ABI3BP gene | CTD | PMID:31601247 | bisphenol A | increases expression | ISO | RGD:1616439 | 6480464 | bisphenol A results in increased expression of ABI3BP mRNA | CTD | PMID:30951980 | bisphenol A | increases expression | ISO | RGD:1349467 | 6480464 | bisphenol A results in increased expression of ABI3BP mRNA | CTD | PMID:27685785 | bisphenol F | increases expression | ISO | RGD:1616439 | 6480464 | bisphenol F results in increased expression of ABI3BP mRNA | CTD | PMID:30951980 | butanal | decreases expression | ISO | RGD:1349467 | 6480464 | butyraldehyde results in decreased expression of ABI3BP mRNA | CTD | PMID:26079696 | cadmium atom | multiple interactions | ISO | RGD:1349467 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ABI3BP mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | RGD:1349467 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ABI3BP mRNA | CTD | PMID:35301059 | calcitriol | decreases expression | ISO | RGD:1349467 | 6480464 | Calcitriol results in decreased expression of ABI3BP mRNA | CTD | PMID:26485663 | carbon nanotube | decreases expression | ISO | RGD:1616439 | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | CGP 52608 | multiple interactions | ISO | RGD:1349467 | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ABI3BP gene] | CTD | PMID:28238834 | chromium atom | decreases expression | ISO | RGD:1349467 | 6480464 | Chromium results in decreased expression of ABI3BP mRNA | CTD | PMID:21437242 | chrysene | increases expression | ISO | RGD:1616439 | 6480464 | chrysene results in increased expression of ABI3BP mRNA | CTD | PMID:26377693 | chrysene | multiple interactions | ISO | RGD:1616439 | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA | CTD | PMID:27858113 | clothianidin | decreases expression | ISO | RGD:1349467 | 6480464 | clothianidin results in decreased expression of ABI3BP mRNA | CTD | PMID:31626844 | crocidolite asbestos | decreases expression | ISO | RGD:1616439 | 6480464 | Asbestos, Crocidolite results in decreased expression of ABI3BP mRNA | CTD | PMID:29279043 | cyclosporin A | decreases expression | ISO | RGD:1349467 | 6480464 | Cyclosporine results in decreased expression of ABI3BP mRNA | CTD | PMID:20106945 | dexamethasone | multiple interactions | ISO | RGD:1349467 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ABI3BP mRNA | CTD | PMID:28628672 | dibenz[a,h]anthracene | decreases expression | ISO | RGD:1616439 | 6480464 | 1 more ... | CTD | PMID:26377693 | dibutyl phthalate | decreases expression | ISO | RGD:1616439 | 6480464 | Dibutyl Phthalate results in decreased expression of ABI3BP mRNA | CTD | PMID:21266533 | dioxygen | multiple interactions | ISO | RGD:1616439 | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of ABI3BP mRNA | CTD | PMID:30529165 | dioxygen | multiple interactions | EXP | | 6480464 | [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in decreased expression of ABI3BP mRNA | CTD | PMID:33729688 | diuron | decreases expression | EXP | | 6480464 | Diuron results in decreased expression of ABI3BP mRNA | CTD | PMID:25152437 | diuron | increases expression | EXP | | 6480464 | Diuron results in increased expression of ABI3BP mRNA | CTD | PMID:21551480 | doxorubicin | decreases expression | ISO | RGD:1349467 | 6480464 | Doxorubicin results in decreased expression of ABI3BP mRNA | CTD | PMID:29803840 | endosulfan | multiple interactions | ISO | RGD:1349467 | 6480464 | Endosulfan inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ABI3BP mRNA] | CTD | PMID:26159488 | endosulfan | decreases expression | EXP | | 6480464 | Endosulfan results in decreased expression of ABI3BP mRNA | CTD | PMID:29391264 | epoxiconazole | decreases expression | ISO | RGD:1616439 | 6480464 | epoxiconazole results in decreased expression of ABI3BP mRNA | CTD | PMID:35436446 | ethanol | decreases expression | ISO | RGD:1616439 | 6480464 | Ethanol results in decreased expression of ABI3BP mRNA | CTD | PMID:29018328 | ethanol | increases expression | ISO | RGD:1616439 | 6480464 | Ethanol results in increased expression of ABI3BP mRNA | CTD | PMID:30319688 | ethanol | affects expression | ISO | RGD:1616439 | 6480464 | Ethanol affects the expression of ABI3BP mRNA | CTD | PMID:30319688 | fenofibrate | decreases expression | ISO | RGD:1349467 | 6480464 | Fenofibrate results in decreased expression of ABI3BP mRNA | CTD | PMID:25572481 | formaldehyde | increases expression | ISO | RGD:1349467 | 6480464 | Formaldehyde results in increased expression of ABI3BP mRNA | CTD | PMID:23649840, PMID:28937961 | fulvestrant | multiple interactions | ISO | RGD:1349467 | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of ABI3BP gene | CTD | PMID:31601247 | glycine betaine | increases expression | EXP | | 6480464 | Betaine results in increased expression of ABI3BP mRNA | CTD | PMID:26391144 | GW 4064 | decreases expression | ISO | RGD:1616439 | 6480464 | GW 4064 results in decreased expression of ABI3BP mRNA | CTD | PMID:26655953 | indometacin | multiple interactions | ISO | RGD:1349467 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of ABI3BP mRNA | CTD | PMID:28628672 | N-nitrosodiethylamine | multiple interactions | ISO | RGD:1616439 | 6480464 | [Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of ABI3BP mRNA | CTD | PMID:24535843 | N-nitrosodiethylamine | increases expression | ISO | RGD:1616439 | 6480464 | Diethylnitrosamine results in increased expression of ABI3BP mRNA | CTD | PMID:24535843 | nickel sulfate | increases expression | ISO | RGD:1349467 | 6480464 | nickel sulfate results in increased expression of ABI3BP mRNA | CTD | PMID:22714537 | oxaliplatin | increases expression | EXP | | 6480464 | oxaliplatin results in increased expression of ABI3BP mRNA | CTD | PMID:25729387 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of ABI3BP mRNA | CTD | PMID:25729387 | ozone | multiple interactions | ISO | RGD:1616439 | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of ABI3BP mRNA, [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of ABI3BP mRNA | CTD | PMID:34911549 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of ABI3BP mRNA | CTD | PMID:33387578 | phenobarbital | multiple interactions | ISO | RGD:1616439 | 6480464 | [Diethylnitrosamine co-treated with Phenobarbital] results in decreased expression of ABI3BP mRNA | CTD | PMID:24535843 | phenobarbital | affects expression | ISO | RGD:1616439 | 6480464 | Phenobarbital affects the expression of ABI3BP mRNA | CTD | PMID:19136022, PMID:23091169 | pioglitazone | multiple interactions | ISO | RGD:1616439 | 6480464 | [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of ABI3BP mRNA | CTD | PMID:27935865 | pirinixic acid | affects expression | ISO | RGD:1616439 | 6480464 | pirinixic acid affects the expression of ABI3BP mRNA | CTD | PMID:19136022 | pirinixic acid | decreases expression | ISO | RGD:1616439 | 6480464 | pirinixic acid results in decreased expression of ABI3BP mRNA | CTD | PMID:20813756 | potassium chromate | decreases expression | ISO | RGD:1349467 | 6480464 | potassium chromate(VI) results in decreased expression of ABI3BP mRNA | CTD | PMID:22714537 | progesterone | increases expression | ISO | RGD:1349467 | 6480464 | Progesterone results in increased expression of ABI3BP mRNA | CTD | PMID:20864642 | resveratrol | multiple interactions | ISO | RGD:1349467 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in decreased expression of ABI3BP mRNA | CTD | PMID:23557933 | sodium arsenate | multiple interactions | ISO | RGD:1349467 | 6480464 | [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of ABI3BP mRNA | CTD | PMID:32525701 | temozolomide | increases expression | ISO | RGD:1349467 | 6480464 | Temozolomide results in increased expression of ABI3BP mRNA | CTD | PMID:31758290 | testosterone | multiple interactions | EXP | | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of ABI3BP mRNA | CTD | PMID:32741896 | testosterone | decreases expression | ISO | RGD:1349467 | 6480464 | Testosterone results in decreased expression of ABI3BP mRNA | CTD | PMID:33359661 | tetrachloromethane | decreases expression | ISO | RGD:1616439 | 6480464 | Carbon Tetrachloride results in decreased expression of ABI3BP mRNA | CTD | PMID:17484886 | tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of ABI3BP mRNA | CTD | PMID:31150632 | tetraphene | multiple interactions | ISO | RGD:1616439 | 6480464 | [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of ABI3BP mRNA | CTD | PMID:27858113 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of ABI3BP mRNA | CTD | PMID:25729387 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of ABI3BP mRNA | CTD | PMID:25729387 | tremolite asbestos | decreases expression | ISO | RGD:1616439 | 6480464 | tremolite results in decreased expression of ABI3BP mRNA | CTD | PMID:29279043 | triadimefon | decreases expression | ISO | RGD:1349467 | 6480464 | triadimefon results in decreased expression of ABI3BP mRNA | CTD | PMID:26705709 | trichostatin A | decreases expression | ISO | RGD:1349467 | 6480464 | trichostatin A results in decreased expression of ABI3BP mRNA | CTD | PMID:24935251 | trichostatin A | increases expression | ISO | RGD:1349467 | 6480464 | trichostatin A results in increased expression of ABI3BP mRNA | CTD | PMID:26705709 | triclosan | increases expression | ISO | RGD:1349467 | 6480464 | Triclosan results in increased expression of ABI3BP mRNA | CTD | PMID:30510588 | triphenyl phosphate | decreases expression | EXP | | 6480464 | triphenyl phosphate results in decreased expression of ABI3BP mRNA | CTD | PMID:30589522 | triptonide | decreases expression | ISO | RGD:1616439 | 6480464 | triptonide results in decreased expression of ABI3BP mRNA | CTD | PMID:33045310 | valproic acid | affects expression | ISO | RGD:1616439 | 6480464 | Valproic Acid affects the expression of ABI3BP mRNA | CTD | PMID:17963808 | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of ABI3BP mRNA | CTD | PMID:29427782 | valproic acid | decreases expression | ISO | RGD:1349467 | 6480464 | Valproic Acid results in decreased expression of ABI3BP mRNA | CTD | PMID:24935251 | vinclozolin | affects expression | EXP | | 6480464 | vinclozolin affects the expression of ABI3BP mRNA | CTD | PMID:19015723 | vinclozolin | decreases expression | EXP | | 6480464 | vinclozolin results in decreased expression of ABI3BP mRNA | CTD | PMID:23034163 | zoledronic acid | decreases expression | ISO | RGD:1349467 | 6480464 | zoledronic acid results in decreased expression of ABI3BP mRNA | CTD | PMID:24714768 | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Welcome {{ username}}
Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{gene.symbol}}: {{ gene.description }}
|
| Save what matters to you |
| {{ loginError }} |
| Sign in with your RGD account |
| Create New Account | Recover Password |
Analyze GeneStrainQTL List |
 Gene Annotator (Functional Annotation) unavailable |
 Gene Annotator (Annotation Distribution) unavailable |
 Variant Visualizer (Genomic Variants) unavailble Variant Visualizer (Genomic Variants) unavailable |
Gene Annotator (Functional Annotation) |
Gene Annotator (Annotation Distribution) |
Variant Visualizer (Genomic Variants) |
 InterViewer (Protein-Protein Interactions) unavailable |
 Gviewer (Genome Viewer) unavailable |
 Variant Visualizer (Damaging Variants) unavailble Variant Visualizer (Damaging Variants) unavailable |
InterViewer (Protein-Protein Interactions) |
GViewer (Genome Viewer) |
Variant Visualizer (Damaging Variants) |
 Gene Annotator (Annotation Comparison) unavailable |
 OLGA (Gene List Generator) unavailable |
 |
Gene Annotator (Annotation Comparison) |
OLGA (Gene List Generator) |
Excel (Download) |
 MOET (Multi-Ontology Enrichement) unavailable |
 GOLF (Gene-Ortholog Location Finder) unavailable |
|
MOET (Multi-Ontology Enrichement) |
GOLF (Gene-Ortholog Location Finder) |
|
||||||||
Gene Ontology Annotations Click to see Annotation Detail View
Biological Process
Cellular Component
Molecular Function
